Quarterly Result12 Feb 2026, 07:53 pm
Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr, Net Profit at Rs 144 Cr
AI Summary
Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal third quarter ended December 31, 2025. The operating revenue for Q3FY26 grew 9% year-on-year to Rs 4,173 crore, with core EBITDA at Rs 1,221 crore, growing 21%. Net R&D investments for the quarter were Rs 249 crore. The company reported a net profit of Rs 144 crore, up 475%.
Key Highlights
- Operating revenue at Rs 4,173 crore, up 9% YoY
- Core EBITDA at Rs 1,221 crore, up 21%
- Net R&D investments at Rs 249 crore, representing 8% of revenue ex-Syngene
- Net profit at Rs 144 crore, up 475%
- Biocon Biologics reported a robust Q3FY26 performance, with EBITDA of Rs 700 crore, up over 44% YoY